Psoriasis – Landscape & Forecast – Disease Landscape & Forecast (G7)

The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson Innovative Medicine’s Tremfya, AbbVie’s Skyrizi) are fiercely competing with the established agents Humira and Stelara, effectively earning a strong position in a crowded market due to their greater efficacy, more-convenient dosing, and faster onset of action. The availability of BMS’s oral TYK2 inhibitor Sotyktu and UCB’s IL-17 A/F dual inhibitor Bimzelx has expanded dermatologists’ treatment armamentarium and increased competition among targeted therapies. Moreover, several oral—and thus more-convenient—agents for psoriasis, including piclidenoson, which has a novel mechanism of action, are expected to launch, further fueling competition in this space. Nevertheless, substantial unmet need in the treatment of psoriasis remains (e.g., agents that induce long-term remission for patients with severe disease, more-affordable therapies for patients with mild disease).

QUESTIONS ANSWERED

• How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq / Lumicef, Bimzelx) and the IL-23 inhibitors (Tremfya, Ilumya, Skyrizi), and where are / will these agents be positioned in the psoriasis treatment algorithm?
• How is the oral TYK2 inhibitor Sotyktu affecting apremilast’s (Amgen’s Otezla) patient share, and how do the two agents compare on efficacy and safety attributes?
• How does the availability of adalimumab biosimilars in the United States impact the psoriasis market?
• What unmet needs remain in the treatment of psoriasis? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?

PRODUCT DESCRIPTION

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.